View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025

Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025 SAN DIEGO, June 16, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that it will host an in-person and virtual R&D Day in New York on Thursday, June 26, 2025, from 9:00 AM to 12:00 PM ET. The event will provide an update including data on Crinetics' early-stage pipeline assets, next steps, and portfolio strategy to drive long-term value. Key topics will include: NETs and beyond – NDC platform with CRN09682Graves’ disease and thyroid eye disease (TED) - TSH antagonistAutosomal polycystic k...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: June 14, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under ...

Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on June 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 74,000 shares of its common stock and granted an aggregate of 48,850 restricted stock unit (“RSU”) awards to 20 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Pla...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: June 7, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: June 4, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: May 31, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: May 28, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: May 24, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: May 23, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Crinetics Pharmaceuticals to Participate in the Jefferies Global Healt...

Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025 SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, 2025 in New York, NY. Jefferies Global Healthcare Conference 2025Company presentation: Thursday, June 5, 2025 at 12:50 p.m. Eastern TimeWebcast link: The live and archived webcast will be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at . If you are interested...

 PRESS RELEASE

Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet...

Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025 New Analysis Shows Treatment with Investigational Paltusotine Resulted in Rapid and Durable IGF-1 Control in Surgically Naïve Acromegaly Patients  Additional Research Includes Acromegaly Symptom Burden and Standard-of-Care Discontinuation Rates  SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced it will present two abstracts at the American Association of Clinical Endocrinology (AACE) Annua...

 PRESS RELEASE

Texas Capital Foundation Awards $250,000 to Texas Nonprofits

Texas Capital Foundation Awards $250,000 to Texas Nonprofits Annual Honors Award program celebrates four organizations that are building a stronger Texas DALLAS, May 14, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital, today announced the recipients of its 2025 Honors Awards. Launched in 2022, the Honors Awards are a signature initiative of the Texas Capital Foundation, awarding $250,000 in total annually to four organizations dedicated to addressing community needs across the state. “We are proud to honor four nonprofits as...

 PRESS RELEASE

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under N...

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on May 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 152,475 shares of its common stock and granted an aggregate of 101,800 restricted stock unit (“RSU”) awards to 35 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”...

 PRESS RELEASE

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results...

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update Regulatory Interactions and Commercial, Medical, and Corporate Preparations On-Track for Paltusotine New Drug Application with September 25, 2025 PDUFA Date   CALM-CAH Phase 3 Study of Atumelnant for the Treatment of Adults with Congenital Adrenal Hyperplasia to Initiate with Uncompromising Primary Endpoint to Normalize Androstenedione Levels with Physiologic Glucocorticoid Replacement R&D Day Scheduled for June 26 to Share Early-Stage Pipeline Strategy and Data $1.3B in Cash, Cash Equiva...

Wedbush Research
  • Wedbush Research
 PRESS RELEASE

Texas Capital Announces Expansion of Corporate and Investment Banking ...

Texas Capital Announces Expansion of Corporate and Investment Banking Division Significant platform investments support advisory, capital markets and trading capabilities DALLAS, May 07, 2025 (GLOBE NEWSWIRE) -- Texas Capital Securities, a subsidiary of Texas Capital Bancshares, Inc. (NASDAQ: TCBI), today announced a significant expansion of the services offered by its Corporate and Investment Bank. The additions to personnel and corresponding enhancements in capabilities build upon the firm’s existing industry-focused Corporate Banking expertise, with significant impact on the breadth ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch